Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

• Bristol-Myers Squibb recently announced positive Phase 3 data for Zenbexus (iberdomide), which demonstrated superior progression-free survival compared to standard of care in relapsed and refractory multiple myeloma, strengthening the company's pipeline and providing a potential future growth driver in a competitive market.
• The company reported strong third-quarter earnings, beating consensus estimates with $2.04 in earnings per share against an expected $1.60, and revenue of $12.97 billion, which exceeded the consensus estimate of $11.74 billion, indicating robust operational performance and top-line growth of 5.7% year-over-year.
• Investors can benefit from a high dividend yield of 4.23%, with the company recently declaring a quarterly dividend of $0.63 per share, offering a substantial income stream that is supported by a payout ratio of 55.51%, which leaves room for financial flexibility.
• The stock is currently trading at $59.51, which is below the average analyst price target of $66.72 and significantly below the 52-week high of $68.64, suggesting potential upside for investors as the consensus rating stands at Moderate Buy with multiple analysts raising their targets recently.
• Bristol-Myers Squibb is experiencing growth from newer medicines such as Reblozyl, which is helping to offset declines from older products, and the company recently secured a label expansion for Camzyos, broadening the commercial opportunity for these newer therapies.